This suggests that blocking EMT-inducing pathways to abrogate invasion and/or metastasis might be an efficacious approach to complement modern melanoma therapies directed against cell proliferation (BRAF- and/or MEK-inhibition) or stimulation of the immune system by checkpoint inhibitor blockade. Here, BRAF is linked to melanoma.